CaliPharms, Inc. (KGET) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCaliPharms, Inc. (KGET) trades at $0.00004. CaliPharms, Inc. is a US-based company focused on the medicinal cannabis industry, specifically THC and CBD beverages. Formerly known as Kleangas Energy Technologies, it rebranded in 2017 to concentrate on cannabis-related ventures. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for KGET: KGET does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
CaliPharms, Inc. (KGET) Healthcare & Pipeline Overview
CaliPharms, Inc. operates within the evolving medicinal cannabis sector, concentrating on THC and CBD-infused beverages. The company, formerly Kleangas Energy Technologies, shifted its focus in 2017. It faces competition in a dynamic market while striving to establish its brand in the cannabis beverage segment.
What Is the Investment Thesis for KGET?
CaliPharms, Inc. presents a high-risk, high-reward investment profile due to its early-stage involvement in the cannabis-infused beverage market. The company's success hinges on its ability to navigate complex regulatory hurdles and establish a strong brand presence. Key value drivers include successful product development, effective marketing, and strategic partnerships. The company's negative P/E ratio of -0.01 and a profit margin of -11861.4% indicate significant financial challenges. Investors should closely monitor the company's cash flow, debt levels, and ability to secure funding for future growth. The high beta of -58.74 suggests extreme volatility relative to the market.
Based on FMP financials and quantitative analysis
KGET Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- Negative P/E ratio of -0.01 reflects the company's current lack of profitability.
- Profit Margin of -11861.4% highlights significant operational inefficiencies and challenges in achieving profitability.
- Gross Margin of 100.0% suggests high potential profitability if operational costs are managed effectively.
- Beta of -58.74 indicates an extremely volatile stock, moving inversely to the market.
Who Are KGET's Competitors?
KGET is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KGET's Key Strengths?
Focus on the growing cannabis beverage market.
- Potential for first-mover advantage in specific regions.
- Experienced management team with knowledge of the cannabis industry.
What Are KGET's Weaknesses?
Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals for growth.
- Lack of established brand recognition.
What Are the Key Risks for KGET?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Stringent regulations and licensing requirements could limit market access.
- Intense competition from larger cannabis companies could erode market share.
- Negative public perception of cannabis could hinder demand growth.
- Limited access to capital and funding could constrain growth plans.
- Product recalls or safety concerns could damage brand reputation.
What Are KGET's Competitive Advantages?
- First-mover advantage in specific regional markets.
- Proprietary formulations for THC and CBD beverages.
- Established relationships with cannabis cultivators and distributors.
What Does KGET Do?
CaliPharms, Inc., headquartered in Temecula, California, is a participant in the United States' medicinal cannabis industry. The company's primary focus is the development and potential distribution of beverages infused with THC and CBD. CaliPharms, Inc. was originally established under the name Kleangas Energy Technologies, Inc., reflecting an earlier business direction. In January 2017, the company underwent a strategic shift, rebranding itself as CaliPharms, Inc. to align with its new focus on the cannabis market. This transition marked a significant change in business strategy, moving away from energy technologies to capitalize on the emerging opportunities within the medicinal cannabis sector. The company is positioning itself to cater to the growing demand for cannabis-infused products, particularly in the beverage segment. CaliPharms, Inc. is working to establish its presence in a competitive market, navigating the regulatory landscape and consumer preferences within the cannabis industry.
What Products and Services Does KGET Offer?
- Engages in the medicinal cannabis industry in the United States.
- Focuses on the development of THC and CBD beverages.
- Aims to capitalize on the growing market for cannabis-infused products.
- Navigates the regulatory landscape of the cannabis industry.
- Seeks to establish a brand presence in the cannabis beverage segment.
- Works to develop and distribute cannabis-infused beverages.
How Does KGET Make Money?
- Develops and potentially distributes THC and CBD-infused beverages.
- Aims to generate revenue through the sale of these beverages.
- Focuses on the medicinal cannabis market in the United States.
What Industry Does KGET Operate In?
CaliPharms, Inc. operates in the rapidly evolving cannabis industry, specifically targeting the infused beverage market. This sector is characterized by changing regulations, increasing competition, and growing consumer acceptance. The market is driven by the increasing legalization of cannabis for medicinal and recreational purposes in various states. CaliPharms faces competition from established players in the beverage industry and emerging cannabis companies. The company's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.
Who Are KGET's Key Customers?
- Consumers seeking medicinal cannabis products.
- Individuals interested in THC and CBD-infused beverages.
- Patients with medical conditions that may benefit from cannabis use.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
CaliPharms, Inc. operates in the Healthcare sector. It is headquartered in Temecula, US. The company is led by CEO Eric Watson. KGET has traded publicly since 2013.
Financial Health
CaliPharms, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
KGET Latest News
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
KGET Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for KGET.
Price Targets
Wall Street price target analysis for KGET.
KGET MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for KGET; grades run from A+ (80-100) to F (below 30).
Leadership: Eric Watson
CEO
Eric Watson serves as the Chief Executive Officer of CaliPharms, Inc. Information regarding Mr. Further research would be required to provide a comprehensive overview of his professional background and qualifications.
Track Record: Due to limited information, it is not possible to assess Eric Watson's track record at CaliPharms, Inc. or his previous accomplishments in other roles. An evaluation of his strategic decisions, company milestones achieved under his leadership, and overall performance requires additional data.
KGET OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CaliPharms, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to less stringent regulations and oversight compared to those listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history, distressed financials, or those that choose not to comply with higher reporting standards. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited liquidity and potential for price volatility.
- Lack of regulatory oversight and potential for fraud.
- Uncertainty regarding financial reporting and disclosure.
- Higher risk of delisting or trading suspension.
- Potential for limited access to capital and funding.
- Verify the company's legal status and registration.
- Obtain and review the company's financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk factors.
- Determine the availability of reliable information and disclosures.
- Understand the liquidity and trading characteristics of the stock.
- Company's registration and good standing with regulatory authorities.
- Availability of some financial information, even if limited.
- Active communication with investors and the public.
- Positive media coverage or industry recognition.
- Existence of a functional website and contact information.
What Investors Ask About CaliPharms, Inc. (KGET) — Healthcare
What do analysts say about KGET stock?
There is no available analyst coverage for KGET stock. The company's micro-cap status and OTC listing may contribute to the lack of analyst attention.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available for this company. OTC stocks are inherently riskier.